Mead Johnson Nutrition Co. elects two to its board of directors
EVANSVILLE, Ind. Mead Johnson Nutrition Company announced Thursday that its board of directors has elected Steven M. Altschuler, M.D., and Elliott Sigal, M.D., Ph.D., to the board. The company said that these additions increase the size of its board to 11.
“We are pleased to have Dr. Altschuler and Dr. Sigal join our board of directors,” said James Cornelius, Mead Johnson Nutrition board chairman. “We’re looking forward to working with them and benefiting from their insights and experience.”
Dr. Altschuler is president, CEO of The Children’s Hospital of Philadelphia, a position he has held since 2000. He joined Children’s Hospital in 1982 as a Fellow in the Division of Pediatric Gastroenterology and Nutrition. Currently, Dr. Altschuler serves on the Board of Directors of the Children’s Miracle Network.
Dr. Sigal is currently EVP, chief scientific officer and president, research and development for Bristol-Myers Squibb. Since joining Bristol-Myers Squibb in 1997, Dr. Sigal has held positions of increasing responsibility in genomics, discovery research and clinical development. He has more than 25 years of combined experience in medicine, research and management.
Prasco enters marketing, distribution agreement with GSK
MASON, Ohio Prasco Labs announced Wednesday it has entered into a marketing and distribution agreement with GlaxoSmithKline.
FLONASE Nasal Spray will be the first product to be marketed under this agreement. Prasco, as GSK’s agent and on GSK’s behalf, will solicit orders for, and distribute, Fluticasone Propionate Nasal Spray to all trade classes in the United States under a GSK/Prasco label.
Fluticasone Propionate Nasal Spray is AB-rated, therapeutically equivalent and substitutable for the brand FLONASE Nasal Spray. Fluticasone Propionate is indicated for the management of the nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients 4 years of age and older.
“We are especially proud to have established this relationship with GlaxoSmithKline, a global leader in the research-based pharmaceutical industry,” said E. Thomas Arington, Prasco CEO. “We look forward to working with GSK to provide more choices for patients in the generics market.”
The Female Health Co. receives FDA approval for new female contraceptive
CHICAGO The Female Health Company announced Wednesday that its FC2 Female Condom received approval from the Food and Drug Administration.
The FC2 is a woman-initiated barrier method that helps to protect against sexually transmitted infections (STIs), HIV/AIDS and unintended pregnancy.
FHC’s lower-cost second generation female condom will now be available for purchase and distribution in the United States. FDA approval also will enable the United States Agency for International Development to procure FC2 for distribution to global HIV/AIDS programs.